Results 71 to 80 of about 235,228 (303)

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand, Seyed Hossein Aghamiri, Saeed Mohmammad Soleymani, Shadiyeh Bararpoor Poshkohi, Samaneh Masoudi, Hadi Esmaily   +5 more
wiley   +1 more source

Study on the content of nurse's prescription of drug for endocrine system and metabolic in China by Delphi method

Huli yanjiu, 2019
ObjectiveTo study the content and form of nurse's prescription of drugs for endocrine system and metabolic in China by using Delphi.MethodsThe two rounds of consultations among 42 experts were carried out by Delphi method,And the final research results ...
HOU Yongchao, HAN Shifan
doaj  

Assessment of prescription sales in Ukraine

Zaporožskij Medicinskij Žurnal, 2013
Currently, the state of the national health system (health) is characterized by a low level of funding for medical and pharmaceutical care and the lack of effective methods of free and preferential dispensing of medicines (drugs) and compensation of ...
N. V. Teterich, L. V. Tereshchenko
doaj   +1 more source

The Rationale for Consuming Cognitive Enhancement Drugs in University Students and Teachers [PDF]

, 2013
Sattler S, Sauer C, Mehlkop G, Graeff P. The Rationale for Consuming Cognitive Enhancement Drugs in University Students and Teachers. PLoS ONE. 2013;8(7): e68821.Cognitive enhancement (CE) is the pharmaceutical augmentation of mental abilities (e.g ...
Carsten Sauer, Mehlkop Guido, Sattler, Sebastian ; https://orcid.org/, Peter Graeff (434233), Carsten Sauer (434231), Guido Mehlkop, Guido Mehlkop (434232), Peter Graeff, Sauer, Carsten ; https://orcid.org/, Graeff Peter, Sattler Sebastian, Sebastian Sattler (434230), Sebastian Sattler, Graeff, Peter, Mehlkop, Guido, Sauer Carsten   +15 more
core   +2 more sources

Vascular Disease, Non‐Steroidal Anti‐Inflammatory Drugs and Risk of Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives A history of vascular disease has been shown to be associated with an increased risk of Parkinson's disease, but this may be due to reverse causation. In addition, non‐steroidal anti‐inflammatory drugs are thought to reduce Parkinson's disease risk, but evidence is inconsistent and confounding by prior vascular disease is possible ...
Clare Wotton, Carol Hermon, Sarah Floud, Gillian Reeves, Isobel Barnes   +4 more
wiley   +1 more source

Mycophenolate Mofetil Treatment Reduces the Risk of Treatment Escalation Due to Vascular Complications in Limited Cutaneous Systemic Sclerosis: Emulation of a Target Trial From the Italian Rheumatology Society SPRING Registry

Arthritis Care &Research, EarlyView.
Objective Mycophenolate mofetil (MMF) use in limited cutaneous systemic sclerosis (lcSSc) is relatively uncommon because of the lower fibrotic burden and the predominance of vascular complications. In vitro observations and clinical data from transplanted patients suggest a protective effect of MMF on endothelial function.
Enrico De Lorenzis, Gerlando Natalello, Rossella De Angelis, Lucrezia Verardi, Dilia Giuggioli, Gianluigi Bajocchi, Lorenzo Dagna, Silvia Bellando‐Randone, Giovanni Zanframundo, Rosario Foti, Fabio Cacciapaglia, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Valeria Riccieri, Elisabetta Zanatta, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Giuseppe Murdaca, Giuseppina Abignano, Giorgio Pettiti, Alessandra Della Rossa, Maurizio Caminiti, Annamaria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Maria Ilenia De Andres, Alessandro Giollo, Cosimo Bruni, Martina Orlandi, Marco Fornaro, Marta Saracco, Cecilia Agnes, Pier Giacomo Cerasuolo, Gabriella Alonzi, Edoardo Cipolletta, Federica Lumetti, Amelia Spinella, Luca Magnani, Corrado Campochiaro, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria‐Grazia Lazzaroni, Franco Franceschini, Elena Generali, Gianna Mennillo, Simone Barsotti, Giuseppa Pagano Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D'Angelo, Franco Cozzi, Fabrizio Conti, Serena Guiducci, Andrea Doria, Carlo Salvarani, Florenzo Iannone, Maria Antonietta D'Agostino, Clodoveo Ferri, Marco Matucci Cerinic, Silvia Laura Bosello, on behalf of the SPRING Italian Registry Collaborators   +77 more
wiley   +1 more source

Evaluation of Acid-Suppressive Medications Prescribing and Usage in Central Hospitals in Abha Region, Saudi Arabia

Ars Pharmaceutica
Objective: The aim of this study was to study and assess the indications of acid suppressive drugs and to find out percentage of irrational prescriptions with acid suppressive drugs.
Khaled M. Alakhali, Hadeel M. Bayoumi, Elham S. Abunakhaa, Manal Ahmed, Nada S. Alqahtani, Rasha A. Jaber, Sahar S. Alasmari, Subhya A. Alshahrani, Zohoor A. Alshahrani   +8 more
doaj   +1 more source

The gender dimension of non medical use of prescription drugs in Europe and the mediterranean region. [PDF]

, 2015
Understanding gender as it relates to drug use and drug use disorders is a critical requirement to developing effective policy and practice responses.
Simeoni, Elisabetta, Clark, Marilyn, Melpomeni Malliori, Minerva, Jasaitis, Ernestas, Jovanović, Mirjana, James, Kryie, Hamdi-Ghoz, Emad, Le Moigne, Phillipe, Palczak, Klaudia, Jauffret-Roustide, Marie   +9 more
core  

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug

Arthritis Care &Research, EarlyView.
Objective We assessed the effectiveness of PrismRA to improve clinical outcomes among patients with rheumatoid arthritis (RA) initiating treatment with a biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD). Methods PrismRA incorporated 19 gene expression features and four clinical features to assess a patient's likelihood of
Fenglong Xie, Timothy Beukelman, Nicholas P. McCormick, Jeffrey R. Curtis   +3 more
wiley   +1 more source

Immune Checkpoint Inhibitor–Related Myositis and Associated Triad Overlap Syndrome

Arthritis Care &Research, EarlyView.
Objective Immune checkpoint inhibitor (ICI) myositis is a rare but a highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all‐cause mortality in these patients.
Selene Rubino, Grant W. Cannon, Brian C. Sauer, Jorge Rojas, Gregory J. Stoddard, Gary A. Kunkel, Jessica A. Walsh, Bryant R. England, Joshua F. Baker, Tawnie J. Braaten   +9 more
wiley   +1 more source